Navigation Links
STERRAD(R) CYCLESURE(R) Biological Indicator is now 24 Hours, Accelerating Instrument Throughput
Date:1/12/2009

IRVINE, Calif., Jan. 12 /PRNewswire/ -- Advanced Sterilization Products (ASP) is pleased to announce that its STERRAD(R) CYCLESURE(R) Biological Indicator readout time has significantly improved from a 48 hour incubation time to only 24 hours. Now, STERRAD(R) System customers can safely record biological indicator results in 50% less time, speeding up instrument throughput in the sterilization department. The product name is also changing to STERRAD(R) CYCLESURE(R) 24 Biological Indicator to reflect this time-saving improvement.

ASP successfully re-engineered the product after receiving feedback from customers requesting a faster incubation period. A faster incubation period keeps sterilization departments moving efficiently as well as limiting the need to purchase duplicate instrument inventories, which is frequently required when waiting for the results of a 48 hour or more biological indicator readout.

"ASP has been providing healthcare organizations with STERRAD(R) System technology and supplies for almost two decades," says Karen Borg, Worldwide Vice President of Marketing for ASP. "We are committed to continuous product innovation and are passionate about designing and marketing infection prevention solutions like the STERRAD(R) CYCLESURE(R) 24 Biological Indicator that not only meet our customers' needs, but often exceed them."

The STERRAD(R) CYCLESURE(R) 24 Biological Indicator can be used with all of ASP's market-leading, low-temperature hydrogen peroxide gas plasma STERRAD(R) Systems: the STERRAD(R) 100NX(TM) System, STERRAD(R) NX(TM) System, STERRAD(R) 100S System, STERRAD(R) 200 System, as well as the STERRAD(R) 50 System. The STERRAD(R) CYCLESURE(R) 24 Biological Indicator is only validated for use in STERRAD(R) Systems.

For information about STERRAD(R) System products, ASP or ASP's line of infection prevention solutions, visit www
'/>"/>

SOURCE Advanced Sterilization Products
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ASP Launches STERRAD(R) Sterility Guide - Eliminating Paperwork and Ensuring Compliance
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Study questions assumptions about human sensitivity to biological motion
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
8. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
9. Biological markers of prostate cancer shed light on cancer burden faced by African-American men
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Biological Link Between BRCA1 and Breast Cancer Detailed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...lif. The newest revolution in microbiology testing...air sheep, a less-hirsute version of the familiar ...nford University School of Medicine, which is to b...nly are these ruminants low-maintenance and parasi...r the microbiology tests necessary to diagnose inf...
(Date:7/3/2009)... through divorce or death in middle age may triple...y 2 (HealthDay News) -- Middle-aged adults who liv... Alzheimer,s disease later in life compared to tho... risk is three times higher among those who are di...dish and Finnish researchers. , The study inclu...
(Date:7/3/2009)... Eva,s Village, ( http://www.EvasVillage....ty, Seeks Buyers for 35mm Michael Jackson Film Pri... Paterson, NJ (PRWEB) July 3, 2009...a non-profit New Jersey anti-poverty charity, seek...int of Michael Jackson,s "Thriller" musi...
(Date:7/3/2009)... Julian Whitaker, MD, a founder of the al...t on searchjointpain.com, a new informational Web ...nditions and solutions. , ...er, MD, a founder of the alternative health moveme...m, a new informational Web site devoted to all asp...
Breaking Medicine News(10 mins):Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 3Health News:Living Alone Increases Odds of Developing Dementia 2Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 2Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 3Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 4Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 5Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2
...hurch of England plans to enter into partnership w...ng to people moving into new homes. // The vicar ...ocese whose special prayers are intended to cover ...Rev Chris Painter, a vicar in Eccles, Greater Manc...
...ndian Institute of Technology (IIT-K) and the Gane...ge have entered into an agreement to carry out joi...echnology that would be of wider interest to all s...have signed a memorandum of understanding (MoU) in...
..., the African leader set new targets to the govern...d this in the Nigerian capital. a major resolution... patients suffering from these diseases should hav...iral (ARV) drugs, care and support. Civil society ...
...ding to the survey conducted among the doctors of ...they were against the proposed legislation of Euth...rs were against this law. Lord Joffe's issued a bi...ctors should be given rights to prescribe drugs th...
Other Medicine News:Health News:New Home New Blessings 2
(Date:6/29/2009)...ire/ -- Vantia Therapeutics, an,emerging pharmace...ugs,targeting large, underserved medical markets,...ical trial of its lead development compound VA1064...483 was successful in producing a,predictable and...termined by,increased osmolality and decreased ur...
(Date:6/28/2009)...29 Data presented,today, in Budap...ovel,once-daily anti-epileptic Zebinix(R)* (esli...d sustained decrease in seizure frequency over the...extension of a pivotal Eslicarbazepine Acetate,ph...Congress for Epilepsy in,Budapest, Hungary. Patie...
(Date:6/26/2009)..., June 27, 2009 Takeda Pharmaceuti...t Takeda Global Research & Development Center,...ary received on June 26 (U.S. time) a complete res...ation (FDA) regarding the Company,s New Drug Appli...l peptidase IV (DPP-4) inhibitor under investigati...
(Date:6/26/2009)... Cancer Recurrence Test MammaPrint,Included in In...tions" issued,on 23 Jun 2009 12:00 GMT, by Agendi...he subheadline was missing from the release as inc...rrected release follows: , , /PRNewswire...est MammaPrint Included in,International St. Gall...
Breaking Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3Life Brokerage Partners Adds New Insurance Carriers 9437 1Life Brokerage Partners Adds New Insurance Carriers 9437 2Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 1Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 2Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 3Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 4Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 5Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 6Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance 28TM 29 9434 7UM Sylvester Offers Community the Gift of Well Being 9432 1UM Sylvester Offers Community the Gift of Well Being 9432 2UM Sylvester Offers Community the Gift of Well Being 9432 3Personal Safes Market to Top 24308 Million by 2011 1854 1Personal Safes Market to Top 24308 Million by 2011 1854 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
The ICP-Monitor for intraventricular, intraparenchymal and epidural measurement of intracranial pressure and for measuring cerebral perfusion pressure and compliance.
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source.
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required.
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)
Medicine Products: